CD274 and neoplasm: In total, 143 Japanese patients with tumor PD-L1 expression ≥ 1% or < 1% from CheckMate 227 Part 1 were randomized to nivolumab plus ipilimumab (n = 66) or chemotherapy (n = 77) (Supplementary Fig. 1).